Merck Unveils Phase 3 Data: Oral PCSK9 Inhibitor Enlicitide Outperforms Rivals in Cholesterol Reduction on March 31, 2026 Apolipoproteins B CORALreef AddOn enlicitide LDL-C Merck PCSK9 inhibitor Phase 3 +
Merck's Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials on June 09, 2025 Administration of prophylactic statin cholesterol CORALreef CORALreef AddOn enlicitide HeFH Hypercholesterolemia, Familial Hyperlipidemia LDL-C Merck oral therapy PCSK9 inhibitor +